Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.
Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.
Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.
